Polaris Market Research Releases Viral Vector and Plasmid DNA Manufacturing Market Outlook 2026–2034: Precision Medicine and Gene Therapy Drive Industry Growth

New industry analysis projects the viral vector and plasmid DNA manufacturing market to reach USD 21.28 billion by 2034 as precision medicine, regenerative therapies, and commercial gene therapy manufacturing accelerate global demand.

Polaris Market Research & Consulting has released its Viral Vector And Plasmid DNA Manufacturing Market Report 2026-2034. The market was valued at USD 6.46 billion in 2025 and is projected to reach USD 21.28 billion by 2034, registering a CAGR of 14.16% during the forecast period. Growth of the market is fueled by rising demand for gene and cell therapies, adoption of precision medicines, and development of regenerative medicines. Commercialization of innovative therapies is expected to boost the demand for quality manufacture of viral vectors and plasmid DNA. Companies are also developing commercial manufacturing plants and innovative bioprocessing technologies that helps to enhance their manufacturing capacities.

Business operations within the market keep on rising as firms work to improve their ability to manufacture. In 2025 and 2026, some of the firms that made announcements of investment and developments include Oxford Biomedica, Lonza, Thermo Fisher Scientific, and Sartorius. These initiatives are improving commercial manufacturing capacity and supporting the growing pipeline of advanced therapies.

“Viral vector and plasmid DNA manufacturing has become a strategic foundation for advanced therapies. These companies that increase manufacturing capabilities and become more compliant and efficient in production will be able to gain the advantages from the next wave of market development.”  — Prajakta Bengale, Senior Healthcare Analyst

Viral Vector And Plasmid DNA Manufacturing Market Investment Signals 2026

Source: Polaris Market Research Analysis

Three Market Developments Reshaping the Viral Vector And Plasmid DNA Manufacturing Industry in 2026

Gene Therapy Manufacturing Is Expanding Commercial Production

Commercial manufacturing of gene therapies is constantly growing within big pharma companies. The capacity of manufacturers is being increased for viral vectors and plasmid DNA to meet the rising demand for clinical and commercial purposes. This situation opens great opportunities for manufacturing services.

Precision Medicine Is Increasing Manufacturing Demand

Rise in precision medicine practices leads to rising demand for personalized biologics and gene therapies. The pharmaceutical industry is adopting modern manufacturing platforms to scale up its production capability. These investments continue to strengthen market growth.

Manufacturing Technologies Are Improving Production Efficiency

Companies are investing in automation, single-use bioprocessing, and digital manufacturing systems. These technologies improve production efficiency, reduce manufacturing timelines, and strengthen product quality. Continuous technology innovation is supporting commercial-scale manufacturing.

Request a free sample copy or read the full market insights : Viral Vector And Plasmid DNA Manufacturing Market Report

About the Polaris Viral Vector And Plasmid DNA Manufacturing Market Report 2026-2034

The report provides detailed analysis of market size, growth forecasts, product trends, manufacturing technologies, regional opportunities, competitive landscape, and investment outlook across the global viral vector and plasmid DNA manufacturing industry. The study is designed for biotechnology companies, pharmaceutical manufacturers, CDMOs, investors, research organizations, and healthcare stakeholders seeking strategic insights into market opportunities and competitive positioning.

Report coverage: Market size and CAGR by product, workflow, and end user | Regional analysis across five regions with country-level breakdowns | Company profiles with financial benchmarking | Regulatory environment analysis | Technology and innovation landscape | Competitive benchmarking | PDF and Excel formats | Customization available by country, region, and segment

Key Companies Profiled

• AGC Biologics
• Catalent Inc.
• Charles River Laboratories
• FUJIFILM Diosynth Biotechnologies
• Kaneka Corporation
• Lonza Group
• Merck KGaA
• Oxford Biomedica
• Sartorius AG
• Thermo Fisher Scientific Inc.
• VGXI Inc.
• WuXi Advanced Therapies

Market Segments Covered in the Viral Vector And Plasmid DNA Manufacturing Market Report

By Product Outlook (Revenue, USD Billion, 2021–2034)

• AAV Vectors
• Lentiviral Vectors
• Retroviral Vectors
• Adenoviral Vectors
• Plasmid DNA

By Workflow Outlook (Revenue, USD Billion, 2021–2034)

• Upstream Processing
• Downstream Purification
• Fill-Finish and Testing

By End User Outlook (Revenue, USD Billion, 2021–2034)

• Gene Therapy Companies
• CDMOs
• Academic & Research Institutes
• Pharmaceutical Companies

By Regional Outlook (Revenue, USD Billion, 2021-2034)

• North America

• US
• Canada

• Europe

• Germany
• France
• UK
• Italy
• Spain
• Netherlands
• Russia
• Rest of Europe

• Asia Pacific

• China
• Japan
• India
• Malaysia
• South Korea
• Indonesia
• Australia
• Vietnam
• Rest of Asia Pacific

• Middle East & Africa

• Saudi Arabia
• UAE
• Israel
• South Africa
• Rest of Middle East & Africa

• Latin America

• Mexico
• Brazil
• Argentina
• Rest of Latin America